Patient 1, a 69-year-old man, developed bilateral lymphedema, greater on right, at the age of 50.
Patient 3-S370T mutation
Female patient 3, age 19 years, developed bilateral lymphedema at the age of 14.
Lymphoscintigraphy showed absence of lymphatic drainage bilaterally of the superficial circulation in all phases of the investigation.
Patient 4-Q420X mutation
Male patient 4, 28 years of age, developed lymphedema in right lower limb at age 19 years, followed by left lower limb with progression up to the knee. At age 22 years, he complained of inguinal pain after physical exercise; a bilateral inguinal ultrasonography showed some subcutaneous lymph nodes of increased volume. The last echographic examination (2014) showed two large right inguinal lymph nodes; lymphedema remained more severe in the right lower limb, in agreement with lymphoscintigraphic findings. Indeed, lymphoscintigraphy showed bilateral slowing of lymph drainage, more evident on the right, where collateral circulation was evident; dermal backflow and anomalous lymph node stops were absent. Scintigraphic imaging definition of the left inguinal and lumbar lymph nodes was normal, whereas that of the right inguinal, iliac and lumbar lymph nodes was reduced, even several hours after injection. This finding might suggest a hypoplastic condition, as the tracer remained mainly at the site of injection, with poor uptake in inguinal nodes and no evidence of dermal backflow (see also patients 5 and 6). Other findings included bicuspid aortic valve, diagnosed at the age of 28. A small conjunctival angioma was also observed in the right eye and a right frontal nevus, which appeared at 16 years of age, that was removed at 27. To introduce the c.826-827delAT mutation into NT-GFP-FOXC2, two site-directed mutagenesis reactions were made consecutively.
First mutagenesis:
The first PCR was performed using forward primer 5'-CAGCGTGGAGAACATCTGACCCTGCGAACGTC-3' and reverse primer 5'-GACGTTCGCAGGGTCAGATGTTCTCCACGCTG-3', which contain complementary sequence to the regions flanking the nucleotide 826, and competent cells were transformed with the amplification product. After TOP10 transformation, was selected a clone containing the NT-GFP-FOXC2(M276X) recombinant plasmid. After purification (PureLink Quick Plasmid Miniprep kit, Invitrogen), potential mutant construct was sequenced.
Second mutagenesis:
The NT-GFP-FOXC2(M276X) recombinant plasmid was used as template for the second site-directed mutagenesis reaction, in order to obtain the NT-GFP-FOXC2(M276DfsX186) vector. The primers designed for this amplification were: forward 5'-CAGCGTGGAGAACATCGACCCTGCGAACGTC-3' and reverse 5'-GACGTTCGCAGGGTCGATGTTCTCCACGCTG-3'. The potential clone was confirmed to contain the required mutation (c.826-827delAT) by a final sequencing
